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A b s t r a c t
Introduction: There are scarce data on the usefulness of manual thrombectomy among patients with non-ST-elevation myocar-
dial infarction (NSTEMI). Early positive reports were not supported by the clinical outcome in the recent TATORT-NSTEMI (Thrombus 
Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Elevation Myocardial Infarction) study. 
Aim: To analyze the long-term outcome of NSTEMI patients treated with manual thrombectomy during percutaneous coronary 
intervention (PCI) in the Polish multicenter National Registry of Drug Eluting Stents (NRDES) study.
Material and methods: There were 13 catheterization laboratories in Poland that enrolled patients in NRDES Registry in 2010–
2011. Patients with a diagnosis of NSTEMI were divided into two groups: those that were treated with manual thrombectomy for 
their primary PCI (T) and those who were not (NT). 
Results: There were 923 patients diagnosed with NSTEMI in NRDES. Aspiration thrombectomy was used in 71 (7.7%) patients 
and the remaining 852 (92.3%) NSTEMI cases were treated without thrombectomy during the index PCI. Thrombectomy was more 
often used in patients with TIMI less than 1, thrombus grades 4 and 5 and older male patients. Percutaneous coronary interventions 
complications such as distal embolization and slow flow were more often observed in the thrombectomy subgroup. Overall mortali-
ty at 1 year was 1.69% in the T and 5.92% in the NT group (p = 0.24 and p = 0.32 after propensity score matching adjustment with 
p = 0.11 in the multivariate logistic regression model).
Conclusions: There was no mortality benefit from thrombus aspiration in NSTEMI patients at 1-year follow-up.
Key words: myocardial infarction, registry, thrombectomy.
Introduction
It has been postulated that there are several strate-
gies that can reduce damage to the heart muscle from 
ischemia-reperfusion injury [1]. Conflicting data on the 
effectiveness of manual thrombus aspiration in ST ele-
vation myocardial infarction (STEMI) patients treated 
with primary percutaneous coronary intervention (PCI) 
have been recently published [2–5]. Updated myocardial 
revascularization guidelines from the European Society 
of Cardiology (ESC) advises the use of thrombectomy 
during primary PCI in STEMI only in selected patients, 
thus degrading its use to class IIb [6]. On the other hand, 
there are hardly any data on the usefulness of manual 
thrombectomy among patients with non-ST-elevation 
myocardial infarction (NSTEMI), with no clear guideline 
recommendations. Early positive reports have not been 
supported by clinical outcome, e.g. in the recent TATORT- 
NSTEMI (Thrombus Aspiration in Thrombus Containing 
Culprit Lesions in Non-ST-Elevation Myocardial Infarc-
tion) study [7, 8]. 
Aim
Our aim was to analyze the real-life registry long-term 
outcome of NSTEMI patients treated with manual throm-
bectomy during PCI in the Polish multicenter National Reg-
istry of Drug Eluting Stents (NRDES) study. The results of 
this all-comers registry should provide complementary and 
contemporary information to the already available data.
Material and methods
The NRDES was a study based on the Polish National 
PCI Registry, which is a  mandatory database for Polish 
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catheterization laboratories since 2004 [9]. An analysis 
of thrombectomy value and effectiveness in STEMI pa-
tients has been previously published using the NRDES 
database [5, 10]. There were 13 high-volume catheter-
ization laboratories with 24/7 PCI duty that enrolled pa-
tients in the NRDES registry in 2010–2011 (12 months of 
enrollment). These were the centers that agreed to fill in 
the extended version of the National PCI Registry called 
NRDES. The main aim of this analysis was to compare 
the outcomes of NSTEMI patients (according to the ESC 
definition) who were treated with manual thrombectomy 
(other types of thrombectomy were excluded from the 
analysis) for their PCI procedure (T) vs those who were 
not (NT). The use of thrombectomy and type of the de-
vice were left at the operators’ discretion and experience 
in each individual case since this was a  registry study 
with no influence on the choice of therapy. Patients who 
were diagnosed with NSTEMI and underwent PCI were 
included in the registry (there were no additional exclu-
sion criteria). The primary end-point of this analysis 
was overall mortality at 12 months. Secondary clini-
cal endpoints included: non-fatal reinfarction, definite 
stent thrombosis (as defined by the Academic Research 
Consortium – ARC) [11], urgent revascularization (PCI 
and/or coronary artery bypass graft (CABG)) and tar-
get vessel revascularization at 1-year follow-up. Major 
adverse cardiovascular events (MACE) were defined as 
the occurrence of death, myocardial infarction, target 
vessel revascularization (TVR) or urgent PCI/CABG (hier-
archical). Thrombus grade category was defined accord-
ing to the original paper [12]. Chronic kidney disease 
was defined as the presence of the disease prior to the 
enrollment or creatinine clearance of less than 60 ml/
min/1.73 m2.
The NRDES study complied with the Declaration 
of Helsinki and was approved by Bioethics Commit-
tee at the Jagiellonian University in Krakow, Poland 
(KBET/120/B/2010 at 30th September 2010). 
Statistical analysis
Data were analyzed according to the established sta-
tistical standards. Categorical variables are expressed as 
percentages (frequency); continuous variables are ex-
pressed as mean ± standard deviation. Normal distribu-
tion was assessed by the Shapiro-Wilk test and equality 
of variances using the Levene test. Between-group dif-
ferences were tested by Student’s or Welch’s t-test for 
normally distributed or by the Mann-Whitney U test for 
non-normally distributed continuous variables. Categori-
cal variables were compared by Pearson’s c2 test or Fish-
er’s exact test for 2 × 2 tables. The risk of MACE in the 
12-month follow-up was determined by univariate and 
multivariate logistic regression.
Due to the observational nature of the study, the 
statistical analysis plan included a balancing for covari-
ates step. Balancing was performed for NSTEMI subject 
populations with thrombectomy performed and not 
performed during PCI. A  one-to-one matched proce-
dure without replacement was performed. We modeled 
the log odds of probability of thrombectomy being per-
formed as a function of selected confounders depending 
on the subpopulation. Due to the small sample size of 
subjects with thrombectomy performed in the NSTEMI 
population, nearest neighbor matching was used. This 
method guarantees that a match is always found for all 
the treated units even if the calculated propensity score 
values are not close. The used confounders list consisted 
of: access site, age, arterial hypertension, chronic kidney 
disease, diabetes mellitus, gender, hyperlipidemia, Killip 
class on admission, lower limb atherosclerosis, clopido-
grel loading dose before cath lab administration, previ-
ous CABG, previous PCI, prior myocardial infarction, prior 
stroke, thrombus grade category, thrombolysis in myo-
cardial infarction (TIMI) before PCI and treated vessel 
(Cx, Dg, IM, LAD, LMCA, Mg, RCA, SvG). Pairs obtained 
by propensity score matching were analyzed using paired 
difference tests. Continuous variables were analyzed by 
paired t-tests if the differences between pairs were nor-
mally distributed; for non-normally distributed differ-
ences the Wilcoxon signed rank test was used. Paired 
categorical variables were compared using the McNe-
mar-Bowker test to assess whether differences between 
subjects with and without thrombectomy performed 
were statistically significant. Values of p less than 0.05 
were considered statistically significant. All calculations 
were done with JMP, Version 9.0.0 SAS Institute Inc., Cary, 
NC, 1989–2007.
Power calculations were performed retrospectively. 
For detecting a difference in MACE rate between patients 
treated with manual thrombectomy and patients with no 
thrombectomy the sample size actually used for type I er-
ror equal to 0.05 post hoc power was 64.2%. The power 
would be 90% if data available for group T were twice 
as large assuming the same rates. It should be noted 
that the post-hoc power analysis has been criticized as 
a means of interpreting negative study results. For this 
reason the results of the analysis should be interpreted 
with caution.
Results
There were 2686 patients enrolled in the NRDES reg-
istry, of whom 923 were diagnosed with NSTEMI (34%). 
Aspiration thrombectomy was used in 71 (7.7%) patients 
and the remaining 852 (92.3%) NSTEMI patients were 
treated without thrombectomy during the index PCI. The 
thrombectomy use ranged from 2.8% to 21% in participat-
ing centers. Patient baseline demographic, angiographic, 
procedural and clinical characteristics in both subgroups 
T or NT unadjusted and adjusted are presented in Tables I 
and II. Thrombectomy was more often used in patients 
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Table I. Baseline demographics and angioplasty characteristics unadjusted
Variable Level NT (n = 852) T (n = 71) Value of p
Age [years] – 62.8 ±11.2 66.3 ±11.7 0.01*
Gender
 
Male 66.2% (564) 80.3% (57) 0.02*
Female 33.8% (288) 19.7% (14)
Prior myocardial infarction Yes 25.9% (221) 16.9% (12) 0.1
Arterial hypertension Yes 82.04% (699) 77.5% (55) 0.3
Hyperlipidemia Yes 70.5% (601) 70.4% (50) 1.0000
Diabetes mellitus Yes 23.7% (202) 23.9% (17) 1.0000
Chronic kidney disease Yes 6.8% (58) 1.4% (1) 0.08
Prior stroke Yes 4.8% (41) 7.04% (5) 0.4
Previous PCI Yes 15.9% (135) 9.9% (7) 0.2
Previous CABG Yes 4.2% (36) 5.6% (4) 0.5
Killip class on admission
 
 
 
I 95.8% (816) 97.2% (69) 0.8
II 2.5% (21) 1.4% (1)  
III 0.8% (7) 0.0% (0)  
IV 0.9% (8) 1.4% (1)  
Arterial access site
 
 
 
Femoral 85.2% (726) 81.7% (58) 0.8
Radial 14.4% (123) 18.3% (13)  
Brachial 0.2% (2) 0.0% (0)  
Other 0.1% (1) 0.0% (0)  
Number of critically stenosed arteries
 
 
 
 
1-vessel disease 38.03% (324) 47.9% (34) 0.3
2-vessel disease 39.0% (332) 39.4% (28)  
3-vessel disease 21.5% (183) 12.7% (9)  
LMCA and RCA disease 0.7% (6) 0.0% (0)  
LMCA disease 0.8% (7) 0.0% (0)  
LMCA Yes 1.3% (11) 1.4% (1) 1.0000
LAD Yes 36.03% (307) 22.5% (16) 0.03*
Dg Yes 8.2% (70) 8.5% (6) 0.8
IM Yes 0.7% (6) 1.4% (1) 0.4
Cx Yes 24.06% (205) 36.6% (26) 0.02*
Mg Yes 14.2% (121) 8.5% (6) 0.2
RCA Yes 29.3% (250) 35.2% (25) 0.3
SvG Yes 1.2% (10) 4.2% (3) 0.07
Arterial graft Yes 0.0% (0) 0.0% (0) –
TIMI before PCI
 
 
 
0 18.3% (156) 73.2% (52) < 0.0001*
1 15.3% (130) 5.6% (4)  
2 19.4% (165) 7.04% (5)  
3 47.07% (401) 14.08% (10)  
GP IIb/IIIa inhibitors during PCI
 
 
Abciximab 2.2% (19) 19.7% (14) < 0.0001*
Eptifibatide 4.6% (39) 15.5% (11)  
None 93.2% (794) 64.8% (46)  
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Variable Level NT (n = 852) T (n = 71) Value of p
TIMI after PCI
 
2 and less 1.8% (15) 2.8% (2) 0.4
3 98.2% (837) 97.2% (69)  
Stent type
 
BMS 66.8% (569) 64.8% (46) 0.8
DES 33.2% (283) 35.2% (25)  
Thrombus grade category
 
 
 
 
1 79.3% (676) 16.9% (12) < 0.0001*
2 11.9% (101) 21.1% (15)  
3 3.05% (26) 12.7% (9)  
4 2.5% (21) 15.5% (11)  
5 3.3% (28) 33.8% (24)  
Thrombus grade category
 
1–3 94.3% (803) 50.7% (36) < 0.0001*
4–5 5.8% (49) 49.3% (35)  
PCI successful Yes 98.9% (843) 97.2% (69) 0.2
Lesion in bifurcation Yes 8.5% (72) 14.08% (10) 0.1
IVUS guided procedure Yes 0.4% (3) 2.8% (2) 0.05
OCT Yes 0.1% (1) 1.4% (1) 0.2
Side branch occlusion during PCI Yes 0.8% (7) 0.0% (0) 1.0000
Coronary artery dissection after stent im-
plantation
Yes 2.6% (22) 4.2% (3) 0.4
Distal embolization during PCI Yes 0.1% (1) 2.8% (2) 0.03*
No-reflow Yes 0.1% (1) 0.0% (0) 1.0000
Slow-flow Yes 2.0% (17) 7.04% (5) 0.02*
Artery perforation Yes 0.1% (1) 0.0% (0) 1.0000
Cardiac tamponade during hospitalization Yes 0.0% (0) 0.0% (0) –
Clopidogrel – loading dose before cath lab
 
 
 
300 mg 5.9% (50) 1.4% (1) 0.1
600 mg 57.4% (489) 70.4% (50)  
Long-term therapy 1.5% (13) 1.4% (1)  
Without clopidogrel 35.2% (300) 26.8% (19)  
Prasugrel – loading dose before cath lab
 
Long-term therapy 1.4% (12) 0% (0) 0.6
Without prasugrel 98.6% (840) 100% (71)  
Clopidogrel – loading dose in cath lab
 
 
 
300 mg 4.7% (40) 2.8% (2) 0.6
600 mg 29.3% (250) 23.9% (17)  
Long-term therapy 1.8% (15) 1.4% (1)  
Without clopidogrel 64.2% (547) 71.8% (51)  
Prasugrel – loading dose in cath lab
 
 
60 mg 1.2% (10) 0% (0) 0.5
Long-term therapy 0.9% (8) 0% (0)  
Without prasugrel 97.9% (834) 100% (71)  
CABG – Coronary artery bypass graft, Cx – circumflex artery, Dg – diagonal artery, IM – intermediate artery, IVUS – intravascular ultrasound, LAD – left anterior 
descending artery, LMCA – left main coronary artery, Mg – marginal artery, OCT – optical coherence tomography, PCI – percutaneous coronary interventions, RCA – 
right coronary artery, SvG – saphenous vein graft, TIMI – Thrombolysis in Myocardial Infarction grade. Data are presented as mean ± standard deviation or number 
(percentage).
Table I. Cont.
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Table II. Baseline demographics and angioplasty characteristics adjusted
Variable Level NT (n = 71) T (n = 71) Matched pairs Value of p
Age – 61.9 ±11.4 62.8 ±11.2 71 0.6
Gender
 
Female 22.5% (16) 19.7% (14) 71 0.7
Male 77.5% (55) 80.3% (57)  
Prior myocardial infarction Yes 18.3% (13) 16.9% (12) 71 0.8
Arterial hypertension Yes 81.7% (58) 77.5% (55) 71 0.6
Hyperlipidemia Yes 70.4% (50) 70.4% (50) 71 1.0000
Diabetes mellitus Yes 21.3% (15) 23.9% (17) 71 0.7
Chronic kidney disease Yes 0.0% (0) 1.4% (1) 71 –
Prior stroke Yes 4.3% (3) 7.04% (5) 71 0.5
Previous PCI Yes 8.5% (6) 9.9% (7) 71 0.8
Previous CABG Yes 4.2% (3) 5.6% (4) 71 0.7
Killip class on admission
 
 
I 100.0% (71) 97.2% (69) 71 –
II 0.0% (0) 1.4% (1)  
III 0.0% (0) 0.0% (0)
IV 0.0% (0) 1.4% (1)  
Access site
 
Femoral 81.7% (58) 81.7% (58) 71 1.0000
Radial 18.3% (13) 18.3% (13)  
Number of critically stenosed
arteries 
 
 
1-vessel disease 36.6% (26) 47.9% (34) 71 0.6
2-vessel disease 40.85% (29) 39.44% (28)  
3-vessel disease 19.72% (14) 12.68% (9)  
LMCA and RCA 
disease
2.82% (2) 0.00% (0)  
LMCA Yes 0.0% (0) 1.4% (1) 71 –
LAD Yes 29.6% (21) 22.5% (16) 71 0.4
Dg Yes 9.9% (7) 8.5% (6) 71 0.8
IM Yes 1.4% (1) 1.4% (1) 71 1.0000
Cx Yes 29.6% (21) 36.6% (26) 71 0.4
Mg Yes 4.2% (3) 8.5% (6) 71 0.3
RCA Yes 35.2% (25) 35.2% (25) 71 1.0000
SvG Yes 2.8% (2) 4.2% (3) 71 0.7
Arterial graft Yes 0.0% (0) 0.0% (0) 71 –
TIMI before PCI
 
 
 
0 64.8% (46) 73.2% (52) 71 0.6
1 5.6% (4) 5.6% (4)  
2 9.9% (7) 7.04% (5)  
3 19.7% (14) 14.08% (10)  
GP IIb/IIIa inhibitors during PCI
 
 
Abciximab 4.2% (3) 19.7% (14) 71 0.03*
Eptifibatide 11.3% (8) 15.5% (11)  
None 84.5% (60) 64.8% (46)  
TIMI after PCI
 
2 and less 4.2% (3) 2.8% (2) 71 0.7
3 95.8% (68) 97.2% (69)  
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Variable Level NT (n = 71) T (n = 71) Matched pairs Value of p
Stent type
 
BMS 63.4% (45) 64.8% (46) 71 0.9
DES 36.6% (26) 35.2% (25)  
Thrombus grade category
 
 
 
 
1 21.1% (15) 16.9% (12) 71 1.0
2 21.1% (15) 21.1% (15)  
3 15.5% (11) 12.7% (9)  
4 14.08% (10) 15.5% (11)  
5 28.2% (20) 33.8% (24)  
Thrombus grade category
 
1–3 42.3% (30) 49.3% (35) 71 0.3
4–5 57.8% (41) 50.7% (36)  
Clopidogrel – loading dose  
before cath lab
 
 
 
300 mg 1.4% (1) 1.4% (1) 71 0.8
600 mg 67.6% (48) 70.4% (50)  
Long-term therapy 0.0% (0) 1.4% (1)  
Without  
clopidogrel
31.0% (22) 26.8% (19)  
Prasugrel – loading dose  
before cath lab
 
Long-term therapy 2.8% (2) 0.0% (0) 71 –
Without prasugrel 97.2% (69) 100.0% (71)  
Clopidogrel – loading dose  
in cath lab
 
 
 
300 mg 5.6% (4) 2.8% (2) 71 0.9
600 mg 16.9% (12) 23.9% (17)  
Long-term therapy 1.4% (1) 1.4% (1)  
Without  
clopidogrel
76.06% (54) 71.8% (51)  
Prasugrel – loading dose  
in cath lab
 
 
60 mg 5.63% (4) 0.0% (0) 71 –
Long-term therapy 1.4% (1) 0.0% (0)  
Without prasugrel 93.0% (66) 100.0% (71)  
CABG – Coronary artery bypass graft, Cx – circumflex artery, Dg – diagonal artery, IM – intermediate artery, LAD – left anterior descending artery, LMCA – left main 
coronary artery, Mg – marginal artery, PCI – percutaneous coronary interventions, RCA – right coronary artery, SvG – saphenous vein graft, TIMI – Thrombolysis in 
Myocardial Infarction grade. Data are presented as mean ± standard deviation or number (percentage).
Table II. Cont.
with TIMI less than 1, thrombus grade 4 and 5, as well as 
older male patients. The PCI complications such as distal 
embolization and slow flow were more often observed in 
the thrombectomy subgroup. Primary and secondary end-
points of the analysis unadjusted and with adjustment by 
propensity score matching are depicted in Tables III and IV. 
Overall mortality at 1 year was 1.7% in group T and 5.9% 
in group NT (p = 0.2 and p = 0.3 after propensity score 
matching adjustment). There was an overall trend of 
more frequent MACE occurrence in the NT group, but it 
was non-significant. Unadjusted Kaplan-Meier survival 
curves and MACE curves for both groups are shown in Fig-
ures 1 and 2. Subgroup analyses showed no significant 
benefit from thrombus aspiration in selected subsets of 
patients (thrombus grade category, age, diabetes, target 
artery). Results from the multivariate logistic regression 
model revealed that thrombectomy use during PCI for 
NSTEMI was not an independent predictor of MACE at 12 
months – Table V.
Discussion
Whereas there are multiple trials and registries ad-
dressing the issue of thrombectomy use in the STEMI set-
ting [3–5, 13, 14], the NRDES study is one of only a few 
existing in the PubMed database that discuss the use of 
manual aspiration thrombectomy in the NSTEMI subgroup 
of patients [15]. The data are complementary to those of 
other trials, since they represent real-life all-comers regis-
try data from multiple centers in Poland. Previous studies 
have discarded its use and have proven no benefit for sur-
rogate endpoints such as microvascular obstruction and 
infarct size [8]. Moreover, even though thrombus burden 
is present in visual assessment in up to 70% of NSTEMI 
cases and the notion of mechanical removal of thrombus 
seems plausible, the results of a  randomized trial and 
in a real life population of the NRDES registry have not 
shown its beneficial effect [7, 16]. Current ESC guidelines 
give no specific recommendation on the use of throm-
bectomy in NSTEMI and have downgraded its use in the 
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Table III. Unadjusted primary and secondary outcomes at 1 year
1-year outcome NT (n = 852) (%) T (n = 71) (%) Value of p
Death 5.9 1.7 0.2
Stent thrombosis 0.4 0.0 1.0000
TVR 2.2 0.0 0.6
reMI 4.7 0.0 0.2
Urgent PCI 8.2 3.7 0.4
Urgent CABG 0.4 3.7 0.049*
Urgent PCI or urgent CABG 8.6 5.6 0.6
MACE 16.8 7.3 0.08
CABG – Coronary artery bypass graft, MACE – major adverse cardiovascular event, PCI – percutaneous coronary intervention, reMI – recurrent myocardial infarction, 
TVR – target vessel revascularization. Data are presented as number (percentage).
Table IV. Adjusted primary and secondary outcomes at 1 year
1-year outcome NT (n = 71) (%) T (n = 71) (%) Matched pairs Value of p
Death 5.8 1.9 52 0.3
Stent thrombosis 0.0 0.0 36 –
TVR 5.6 0.0 36 –
reMI 2.8 0.0 36 –
Urgent PCI 11.1 5.6 36 0.4
Urgent CABG 0.0 5.6 36 –
Urgent PCI or CABG 11.1 8.3 36 0.7
MACE 17.5 10.0 40 0.4
CABG – Coronary artery bypass graft, MACE – major adverse cardiovascular event, PCI – percutaneous coronary intervention, reMI – recurrent myocardial infarction, 
TVR – target vessel revascularization. Data are presented as number (percentage).
Figure 1. Kaplan-Meier survival curves for 1 year 
observation in T (thin line) vs. NT (thick line) groups 
respectively (log-rank test; adjusted results; p = 0.3)
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Figure 2. Kaplan-Meier major adverse cardiovas-
cular event curves for 1 year observation in T (dot-
ted line) vs. NT (fine line) groups respectively (log-
rank test; adjusted results; p = 0.2)
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Table V. Logistic regression models for 12-month major adverse cardiovascular event occurrence
Variable OR Univariate Multivariatea Multivariateb
OR (95% CI) Value of p OR (95% CI) Value of p OR (95% CI) Value of p
Age 10 years 1.3 (1.07–1.6) 0.009* 1.2 (1.02–1.5) 0.03* 1.3 (1.03–1.5) 0.02*
Gender Male/female 0.8 (0.5–1.3) 0.4
Prior myocardial infarction Yes/no 1.8 (1.08–2.8) 0.02* 1.6 (1.0–2.6) 0.05 1.8 (1.1–3.02) 0.02*
Prior stroke Yes/no 1.4 (0.5–3.3) 0.5
Previous PCI Yes/no 1.3 (0.7–2.4) 0.3
Previous CABG Yes/no 0.4 (0.07–1.5) 0.2 0.3 (0.05–1.2) 0.09
Arterial hypertension Yes/no 0.8 (0.5–1.3) 0.3 0.6 (0.4–1.1) 0.1
Hyperlipidemia Yes/no 1.0 (0.6–1.6) 0.9
Diabetes mellitus Yes/no 1.3 (0.8–2.1) 0.3
Chronic kidney disease Yes/no 1.8 (0.8–3.8) 0.2
TIMI 3 before PCI Yes/no 0.8 (0.5–1.3) 0.4
TIMI 3 after PCI Yes/no 0.6 (0.2–2.6) 0.4
LMCA Yes/no 2.7 (0.6–10.2) 0.2
LAD Yes/no 0.9 (0.6–1.4) 0.6
Access site Femoral/radial 1.2 (0.7–2.2) 0.8
Stent type BMS/DES 1.1 (0.7–1.8) 0.6
Thrombectomy Yes/no 0.4 (0.1–1.0) 0.04* 0.5 (0.1–1.2) 0.1 0.5 (0.1–1.2) 0.1
aModel fitted using backward stepwise regression (all listed variables initially included) with the Wald c2 p < 0.05 threshold stopping rule with the locked thrombec-
tomy (the Wald c2 computed as (Estimate/Std Error)2 for the hypothesis that the parameter is zero shows the prior myocardial infarction parameter to be statistically 
significant with p = 0.0499; at the same time the likelihood-ratio c2 test calculated as twice the difference of the log-likelihoods between the full model and the model 
constrained by the hypothesis to be tested shows the parameter to be not statistically significant with p = 0.0539). bModel fitted using backward stepwise regression 
(all listed variables initially included) with the minimum corrected Akaike information criterion stopping rule with the locked thrombectomy. CABG – Coronary artery 
bypass graft, CI – confidence interval, LAD – left anterior descending, LMCA – left main coronary artery, OR – odds ratio, PCI – percutaneous coronary intervention, 
TIMI – thrombolysis in myocardial infarction grade. Data are presented as odds ratio with 95% confidence interval and number (percentage).
STEMI population [6], largely due to the negative results 
of recent large trials and a meta-analysis [2–4]. Moreover, 
a recent survey revealed that aspiration thrombectomy is 
used routinely by 36% of physicians during PCI for STEMI 
and selectively in 60% of cases [17]. There is also reported 
a strong belief (89%) among interventional cardiologists 
that a confirmatory thrombectomy trial is needed. That 
is why we believe it is important to show our data as an-
other layer of evidence in the poorly investigated issue of 
thrombectomy use in NSTEMI patients in contrast to the 
STEMI subgroup, which even in the presence of multiple 
data is still burdened with uncertainty as to the proce-
dure. In the NRDES registry, the use of thrombectomy in 
NSTEMI patients was fairly rare (in up to 8% of patients) 
in comparison to STEMI [5], which suggests that it may 
have only been used in cases that seemed the most suit-
able ones for thrombus aspiration. Even though a bias to 
use thrombus aspiration in the case of a large thrombus 
burden, in older male patients and in the circumflex ar-
tery has been noted, still it was less pronounced than in 
the same population for the STEMI subgroup [5]. Half of 
the patients in our study where thrombectomy was used 
had a thrombus grade category 4–5, whereas in the no 
thrombectomy group it was only 5.8%. This means that if 
thrombus was visible, aspiration was considered by the 
attending PCI operator. This was in fact the greatest bias 
that needed to be addressed by the statistical method-
ology to account for obvious baseline differences. The 
numerical difference between the thrombectomy and no 
thrombectomy group with regard to 1-year mortality both 
unadjusted and adjusted by propensity score matching is 
substantial but not statistically significant. Even though 
the T group was considered higher risk by demographics 
and angiography, it revealed lower mortality in long-term 
observation. Nevertheless, it should be noted here that 
the difference was not significant when either adjust-
ed or unadjusted data were compared and may simply 
be a  matter of chance, not reflecting a  real difference. 
The observed mortality rates are also lower than in the 
previously published Polish data [18], which may reflect 
changing trends in treatment of acute MI in Poland over 
the years [19]. All the above might be the trigger to initi-
ate a large trial focused on clinical endpoints in a select-
ed cohort of NSTEMI patients with a  visible thrombus 
burden. The NSTEMI patients are a heterogeneous group 
of patients often with a more aggravating past medical 
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history and outcome even in comparison to STEMI [20, 
21] and certainly require scrutinized research on a specif-
ic subgroup of patients.  
There was no angiographic source data verification by 
an independent PCI operator or corelab. No standardized 
procedure description was available and thrombectomy 
was performed according to local standards. Finally, the 
subgroup of NSTEMI patients with thrombectomy was 
too small (smaller than in e.g. the TATORT trial) to draw 
any definite conclusions. 
Conclusions
Use of aspiration thrombectomy in NSTEMI is rare 
in real life populations. There exists a  selection bias for 
performing thrombectomy, especially in patients with 
a  large thrombus burden. There was no mortality bene-
fit after statistical adjustments from thrombus aspiration 
in NSTEMI patients at 1-year follow-up in this real-life 
all-comers multicenter registry. The rate of MACE was also 
similar. 
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